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ABSTRACT
Wilms tumour (WT) is the most common renal tumour in children. Most WT 
patients respond to chemotherapy, but subsets of tumours develop resistance to 
chemotherapeutic agents, which is a major obstacle in their successful treatment. 
Multidrug resistance transporters play a crucial role in the development of resistance 
in cancer due to the efflux of anticancer agents out of cells. The aim of this study was 
to explore several human multidrug resistance transporters in 46 WT and 40 non-
neoplastic control tissues (normal kidney) from patients selected after chemotherapy 
treatment SIOP 93–01, SIOP 2001. Our data showed that the majority of the studied 
multidrug resistance transporters were downregulated or unchanged between 
tumours and control tissues. However, BCRP1, MDR3 and MRP1 were upregulated in 
tumours versus control tissues. MDR3 and MRP1 overexpression correlated with high-
risk tumours (SIOP classification) (p = 0.0022 and p < 0.0001, respectively) and the 
time of disease-free survival was significantly shorter in patients with high transcript 
levels of MDR3 (p = 0.0359). MDR3 and MRP1 play a role in drug resistance in WT 
treatment, probably by alteration of an unspecific drug excretion system. Besides, 
within the blastemal subtype, we observed patients with low MDR3 expression 
were significantly associated with a better outcome than patients with high MDR3 
expression. We could define two types of blastemal WT associated with different 
disease outcomes, enabling the stratification of blastemal WT patients based on the 
expression levels of the multidrug resistance transporter MDR3. 
INTRODUCTION 
Wilms tumour (WT), also called nephroblastoma, 
is an embryonal malignant neoplasm of the kidney 
accounting for 6–7% of all childhood cancers [1–3]. WT is 
the most common renal tumour in children before the age 
of five years [1, 4–6]. Histologically, the usual appearance 
of WT is that of a mixed pattern, with variable proportions 
of three cellular components (blastemal, epithelial, and 
stromal). Each one of these cellular elements may show 
different degrees of differentiation [7].
Children’s Oncology Group (COG) and the 
International Society of Paediatric Oncology (SIOP) are 
the two major groups which have great contributions 
in the management of WT. Both develop two different 
approaches or protocols of the diagnosis and treatment 
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of WT [6, 8–9]. Those two protocols are currently used: 
The COG in North America develops a system based in an 
upfront surgery (nephrectomy) to accurately assess tumour 
stage and histology [3, 10]. In Europe, SIOP delays 
nephrectomy 4–6 weeks favoring upfront chemotherapy 
and reducing complications of surgery and tumour spillage 
[3, 11]. Both collaborative groups have proven valuable 
in predicting outcomes and the different approaches of 
treatment have shown almost equivalent clinical outcomes 
[10, 12–13].
Three risk groups (low, intermediate, and high) were 
defined by the SIOP Pathology system (SIOP 93–01, SIOP 
2001), based on the percentage of overall necrosis and the 
predominant cell type in the residual viable cells [14–15]. 
Although in most cases of WT such therapy induces a 
considerable degree of tumour shrinkage and the overall 
survival is greater than 90%, a proportion of cases show 
a limited volume reduction and retain an abundance of 
blastemal tissue post-chemotherapy. These are stratified 
as high-risk blastemal cases and have a poor prognosis 
[16]. One of the biggest problems for patients with poor 
prognosis is resistance to standard chemotherapy [17]. 
Patients with blastemal WT represent a chemoresistant 
cohort requiring more intensive adjuvant treatment [18].
Several mechanisms have been described that could 
contribute to chemoresistance: Nonspecific expulsion 
of drugs out of the cell is probably the best studied 
resistance mechanism and mainly related to the action 
of certain proteins [19–20]. These proteins are present 
in many normal tissues of the human body as well as 
in tumours. The fact that many of these have secretory-
excretory tissue functions (kidney, liver, gastrointestinal 
epithelium and respiratory epithelium) suggests that 
multidrug resistance proteins could play the physiological 
function of protection against exogenous toxins [21–23]. 
Over the years, a number of genes have been identified as 
being involved in multidrug resistance but the molecular 
mechanisms of drug resistance in WT remain poorly 
understood. The multidrug resistance transporters are 
classified into two groups: A) Proteins belonging to the 
family of transporters known as ABC transporters (ATP-
binding cassette), which are located in the cell membrane. 
Members of this family are involved in the active transport 
of many molecules through the cell membrane. Some of 
the main members are P-glycoprotein (PGP), multidrug 
resistance-associated protein (MRP) and breast cancer 
resistance protein (BCRP), which act as “efflux pump” 
decreasing the intracellular accumulation of different 
substances, including many cytostatic drugs [24–25]. B) 
Non-ABC transporters such as related protein in lung 
resistance (LRP) or Major Vault Protein (MVP): Vault 
human complex comprises the vault higher molecular 
weight protein (MVP) and two minor vault proteins 
(VPARP and TEP1), plus untranslated RNA molecules. 
Vault proteins are found in the cytoplasm, probably 
associated with cytoplasmic vesicles, and a small part in 
the nuclear membrane, particularly in the nuclear pore 
complex [26–28].
The role of multidrug resistance transporters in WT 
is not well characterized. Since 1997, few studies have 
addressed the expression of multidrug resistance transporters 
in this prevalent tumour. These manuscripts provided data 
on the main transporters but did not provide a complete 
expression profile. Moreover, the studies showed a reduced 
number of cases, a lack of suitable statistical analysis and 
contradictory results [26, 29–33]. It is important to elucidate 
the role of multidrug resistance transports in WT as they 
may form the basis of one of the possible reasons for a WT 
patient’s treatment failure. The aim of the present study was 
to analyze the expression profiling of multidrug resistance 
transporters in frozen and in paraffin-embedded samples 
from WT patients and correlate these results with different 
clinicopathological parameters. 
RESULTS 
Differences in the gene expression profile of 
multidrug resistance genes between control 
kidneys and Wilms tumour samples 
To determine the role of multidrug resistance 
transporters in WT, we performed gene expression profiling 
of nine multidrug resistance transporters in WT frozen 
samples (Series 1). Previous to qRT-PCR analysis, we 
assessed the best endogenous gene by geNorm v3 software 
and evaluated the most stable reference genes from a set of 
tested genes in a given cDNA sample panel (kidney and 
WT samples). A gene expression normalization factor was 
calculated for each tissue sample based on the geometric 
mean of a user-defined number of reference genes: B2M, 
GAPDH, HRPT1 and TPT1. The best gene for expression 
normalization was TPT1. Then, through qRT-PCR, levels 
of mRNAs encoding transporters in WT were compared 
to those of normal kidneys. We found that expression 
of BCRP1 (breast cancer resistance protein), MDR3 
(Multidrug resistance 3) and MRP1 (Multidrug resistance-
associated protein 1) were significantly higher in WT 
patient samples than in control samples. We also observed a 
significantly lower expression of MRP2, MRP3 (Multidrug 
resistance-associated protein 2 and 3) and MVP1 in WT 
than in control samples (Figure 1A). Next, we analyzed 
the mRNA levels of these genes in paired samples (n = 40) 
and compared its expression between normal kidney 
and WT (Figure 1B). We observed the same expression 
pattern as for the non-paired samples. However, we did 
not find any differences in the minor vault genes (vPARP 
and TEP1) in any of the analyses done. Therefore, in WT 
samples we observed a differential expression pattern in 
the transporter genes BCRP1, MDR3 and MRP1, which 
could confer resistance to chemotherapy treatment.  
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Overexpression of MDR3 and MRP1 correlated 
with blastemal subtype and high-risk prognosis 
of Wilms tumour patients 
The determined pattern of gene expression provides 
information on which transporter genes have increased 
expression in WT (and may confer the tumour more 
resistance to treatment) and those that have a decreased 
expression (the tumour would be more sensitive to 
treatment). Consequently, we compared the tumour 
expression of multidrug resistance transporter genes with 
WT clinicopathological characteristics. We analyzed the 
risk (low, intermediate and high), stage (I to IV), and 
tumoural subtype (blastemal, epithelial and stromal) of 46 
WT samples (Series 1). We observed that only MDR3 and 
MRP1 overexpression showed a significant relationship 
with clinicopathological parameters. The other multidrug 
resistance transporters in the series did not correlate with 
those parameters (data not shown). Surprisingly, MDR3 
and MRP1 expression showed a significant increase in 
high-risk tumours compared with low or intermediate 
risk. Also, we appreciated a progressive increase in MDR3 
expression as the degree of risk was increased (Figure 2A). 
On the other hand, blastemal tumours showed a stronger 
expression in MDR3 and MRP1 than epithelial or stromal 
WT (Figure 2B). Subsequently, we checked whether we 
could detect the same differences in MDR3 and MRP1 
protein levels between kidney and tumour samples and 
between high and intermediate risk WT samples. We 
extracted protein from 5 kidneys and 13 WT frozen samples 
and analyzed the expression by western blot (Series 1). We 
observed that high-risk WT samples had more MDR3 and 
MRP1 expression than normal kidneys and intermediate-
risk tumours (Figure 2C). Therefore, MDR3 and MRP1 
transcript and protein levels were increased in high-risk 
tumours. We were interested to evaluate whether the 
expression of these two multidrug resistance transporters 
was correlated. Our results show that in normal tissue 
samples there was no correlation in expression between 
the two genes, but in WT samples there was a positive 
correlation (Figure 2D). So, MDR3 and MRP1 were 
increased in high-risk tumours, particularly in blastemal 
tumours, and there was a positive correlation between 
them. This result indicates that the multidrug resistance 
transporters MDR3 and MRP1 could be determinant of 
treatment resistance of malignant WT patients.  
Immunohistochemical detection confirms MDR3 
and MRP1 overexpression in Wilms high-risk 
tumours
A total of 31 formalin-fixed paraffin-embedded 
FFPE samples (Series 2) were analyzed using 
immunohistochemical detection with selected antibodies. 
We analyzed the presence/absence of MDR3 and MRP1 
expression in WT. Similar to the analysis of mRNA levels 
and in total protein extracts (Figures 1 and 2), we observed 
a differential expression between kidneys and WT as well 
as between intermediate- and high-risk tumours. All of 
the normal kidney samples either expressed weakly or 
were negative for MDR3, while MRP1 expression was 
weak to moderate. The high-risk WT samples had higher 
expression than normal kidney or intermediate-risk 
WT samples (Figure 3A). Besides an evaluation of the 
Figure 1: Profiling of the transcript expression of multidrug resistance genes from frozen tissue samples (normal 
kidney and WT tissues) reveals changes of multidrug resistant gene expression in WT samples. (A) Analysis of expression 
in 40 control kidney and 46 WT samples. (B) Paired analysis between kidneys (n = 40) and WT (n = 40). For all the analyses, *p < 0.05; 
**p < 0.01; ***p < 0.001. NS, not significant.
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levels of expression, the use of immunohistochemistry 
allowed us to distinguish the subcellular localization of 
the two multidrug resistance transporters. We observed 
plasma membrane and cytoplasmic expression for both 
transporters. By Fisher´s exact test we confirmed a 
statistically significant difference in expression in high-
risk expression tumours. There was MDR3 expression in 
71.43% of high-risk tumours compared with only 20.83% 
of intermediate-risk tumours. Likewise, MPR1 expression 
in high-risk tumours was 85.72% with respect to 29.17% 
in intermediate-risk tumours (Figure 3B). These significant 
differences confirm the relevance of MDR3 and MRP1 in 
high-risk WT.
High expression of MDR3 correlated with 
reduced disease-free survival in WT patients
According to our data, MDR3 and MRP1 were more 
highly expressed in high-risk and in blastemal subtype 
WT. The next step was to correlate these results with 
the clinical parameters of patients (Series 1). Previous to 
this analysis, we confirmed that our patient sample series 
was representative. We analyzed by Kaplan-Meier the 
relation between disease-free survival (a clinical prognosis 
marker) with tumour subtype and risk. We confirmed that 
patients with blastemal subtype or with high-risk tumours 
had a reduced disease-free survival (Figure 4A and 4B) 
and were significantly more likely to relapse. These 
results confirm that our series represents what has been 
previously described in other published studies. Blastemal 
predominant and high-risk WT is more aggressive than 
other subtypes and has a poor outcome [16–17]. Next, we 
analyzed disease-free survival versus MDR3 and MRP1 
transcript expression. We used a median cut off because it 
is more representative and less biased. Our results showed 
that WT patients with high transcript levels of MDR3 had 
a significantly poorer prognosis than WT patients with low 
mRNA levels (Figure 4C). We performed an analogous 
analysis with MRP1 but it did not show any statistical 
differences between expression levels (Figure 4D). In 
conclusion, MDR3 and MPR1 overexpression could be 
important biomarkers in high-risk WT but only the high 
expression of MDR3 confers poor prognosis in treated 
patients.
The level of MDR3 expression can be used to 
stratify the Wilms tumour blastemal subtype
The WT subtype with the worse clinical outcome 
is blastemal predominant. Applying the same cut off as 
in Figure 4C–4D, the number of blastemal WT samples 
in Series 1 with low or high expression levels of MDR3 
was 5 and 6 respectively, with similar numbers for MRP1 
expression (Figure 5A). From the Series 1 samples we 
obtained a positive and significant correlation between 
MDR3 and MRP1 transcript expression in blastemal 
Figure 2: Overexpression of MDR3 and MRP1 in tumour samples correlated with poor prognosis. (A) Significantly 
higher expression of MDR3 and MRP1 in high-risk WT than normal kidney, low and intermediate risk tumours. (B) Blastemal predominant 
tumoural subtype presented more MDR3 and MRP1 expression levels than kidney, low- and intermediate-risk tumours. (C) Protein 
expression of MDR3 and MRP1 in normal kidney and WT samples. High-risk WT samples had more MDR3 and MRP1 protein expression 
than kidneys and intermediate risk tumours. (D) Significant positive correlation between MDR3 and MRP1 in WT but not in normal kidney 
samples. For all the analyses, *p < 0.05; **p < 0.01; ***p < 0.001. NS, not significant.
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tumour samples only (Figure 5B). Similar to the 
correlation previously identified in Figure 2D for all 
samples, blastemal WT with high MDR3 expression also 
showed high levels of MRP1. 
Surprisingly, we found blastemal WT samples 
with both high and low expression of MDR3 and MRP1. 
Therefore, we were interested to examine whether the 
differences in expression had any clinical relevance. 
We analyzed by Kaplan-Meier the relation between 
disease-free survival and transcript expression levels. 
We observed that patients with high MDR3 expression 
showed a higher relapse rate than patients with low MDR3 
expression (p = 0.0328). In fact, the subgroup with low 
expression did not relapse (Figure 5C). However, we 
could not confirm the relation between the progression of 
patients with blastemal predominant tumours and MRP1 
expression levels statistically due to the small sample size 
(Figure 5D). To confirm MDR3 and MRP1 as possible 
clinical markers for blastemal subtype stratification, 
further to the analysis of gene expression by qRT-PCR, we 
checked whether we could stratify WT subtype cases by 
the level of IHC labeling. There were only four blastemal 
cases in our TMA (Series 2) thus we were unable to do a 
statistical comparison. Nevertheless, we confirmed by IHC 
that there were different MDR3 and MRP1 expression 
levels in blastemal WT samples. We identified two types 
of blastemal WT, i) those with low MDR3 and MRP1 
expression, and ii) those with high expression of both 
proteins (Figure 5E).
DISCUSSION
Predicting the clinical behavior and prognosis of 
Wilms tumours can be difficult. Currently, the prediction 
of treatment outcome – whether the WT patient will 
respond to chemotherapy or not – is mainly based on the 
histopathology and stage of disease at the time of resection 
[34]. The aim of this study was to identify novel molecular 
prognostic markers by characterization of the expression 
profiles of multidrug resistant genes in WT samples. 
The role of multidrug resistant transport-associated 
proteins in chemotherapy-acquired drug resistance and 
its correlation with the evolution of the disease has not 
been fully investigated for WT. Our results showed a 
Figure 3: MDR3 and MRP1 immunohistochemical analysis expression in 31 WT patients from Tissue MicroArray. 
(A) Immunohistochemical detection of MDR3 and MRP1 in kidney and intermediate and high-risk WT (20× and 40× amplification). High-
risk tumours showed a stronger expression of MDR3 and MRP1 than kidney and intermediate-risk tumours. (B) Significant correlation 
between negative and positive expression of MDR3 and MRP1 in intermediate- and high-risk WT samples. 
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differential expression pattern of specific multidrug 
resistance genes after the treatment of WT patients. The 
majority of multidrug resistance transporters studied 
was downregulated or unchanged between tumours and 
control tissues. However BCRP1, MDR3 and MRP1 
were upregulated in tumours versus control tissues. 
Among the multidrug resistant transporters studied, 
only MDR3 and MRP1 showed a significant correlation 
with clinicopathological parameters. Specifically, our 
retrospective results showed an increase in high-risk 
and blastemal predominant subtype tumours associated 
with MDR3 and MRP1 expression. There was a positive 
correlation between MDR3 and MRP1 expression in 
tumours but not in normal kidney. We suppose that the 
increased expression of the two transporters would confer 
more resistance to treatment in WT, as has recently been 
demonstrated in ovarian cancer and in several different 
cancer cell lines [35–36].
Confirming our data, many studies have highlighted 
the importance of MDR3 or MRP1 in malignant disease. 
A study of chronic lymphocytic leukemia reported 
the increased expression of MDR3 in patients with 
advanced disease in comparison to early stages [37–38]. 
Furthermore, in pediatric soft tissue sarcomas after 
chemotherapy, an increase in MDR3 gene expression 
was described as well as in cholangiocarcinoma and 
cirrhosis [39]. For MRP1, high levels of the gene were 
associated with poor prognosis and high histological 
grade in childhood neuroblastoma [40–42], soft tissue 
sarcoma [43], and non-small cell lung cancer [44–46], 
and with recurrence in breast cancer patients who were 
treated with chemotherapy [47]. To our knowledge, only 
one previously reported study suggested the existence 
of a common expressing regulatory mechanism between 
MDR3 and MRP1 in high-risk tumours such as breast 
cancers and nephroblastoma [48].
Although MDR3 and MRP1 were overexpressed in 
high-risk WT and we found a positive correlation between 
them, only MDR3 expression was negatively correlated 
with disease-free survival. In colorectal cancer, the disease 
free interval of patients treated by adjuvant chemotherapy 
was significantly shorter in patients with low transcript 
levels of MDR3 [49]. In addition, the overall survival of 
liver cancer patients tended to be longer in those patients 
with high MDR3 and MRP1 expression compared to 
the control group [50]. Our results did not show any 
relation between MRP1 and disease-free survival, but 
other studies demonstrated an association with patient 
survival in nephroblastoma [29] and with shorter time of 
disease progression in breast cancer [51]. The discrepancy 
in results obtained in different tumours may be due to 
different factors such as epigenetics, microenvironment, 
or compensation between different multidrug resistance 
proteins and altered tumour homeostasis versus healthy 
Figure 4: Overexpression of MDR3 gene is associated with reduced disease-free survival of WT patients. (A) Blastemal 
predominant subtype conferred a reduced period of disease-free survival compared to the Epithelial and Stromal subtypes. (B) Tumoural 
risk Kaplan-Meier showed reduced disease-free survival in patients with high-risk tumours. (C) Disease-free survival of patients with high 
MDR3 expression was significantly shorter than those with low MDR3 expression. (D) MRP1 Kaplan-Meier disease-free survival according 
to the transcript tumour expression did not show stadistical differences. 
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Figure 5: MDR3 gene expression is associated with disease-free survival in the blastemal WT subtype and allows 
the stratification of patients. (A) Distribution of the number of samples with high expression versus non/low MDR3 and MRP1 
expression, respectively. The cutoff value corresponds to the median expression level of each gene in WT. (B) Correlation study of the 
expression of MRP1 and MDR3 in blastemal tumour samples. (C) MDR3 Kaplan-Meier plot with disease-free survival according to the 
transcript blastemal tumour expression showed statistically significant differences between low and high expression. No patients with non/
low expression MDR3 relapsed. (D) MRP1 Kaplan-Meier disease-free survival according to the transcript blastemal tumour expression did 
not show statistically significant differences. (E) Immunohistochemical detection of MDR3 and MRP1 in blastemal WT patient samples 
from tissue microarray (20× and 40× amplification).
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organs by inhibiting or overexpressing different multidrug 
resistance genes.
Predicting the clinical response of WT patients to 
chemotherapy treatment with current clinical tools can 
be difficult; therefore, there is a real need to identify 
molecular prognostic markers. The blastemal subtype 
of nephroblastoma after pre-operative chemotherapy 
is strongly associated with adverse outcome [52]. Our 
results showed that MDR3 could be a prognostic marker 
in blastemal and high-risk WT. Surprisingly, we observed 
two different blastemal WT patients defined by MDR3 
and MRP1 expression, and relapse was associated with 
high MDR3 expression in blastemal WT. Results in MRP1 
showed the same behavior but the number of samples 
was not high enough to reach statistical significance. 
Nevertheless, we observed a positive correlation between 
MDR3 and MRP1 in blastemal WT, stratifying blastemal 
WT into two groups with different clinical outcomes and 
confirming the importance of the multidrug resistance 
transports in blastemal WT. In accordance with our data, 
Barroca suggested that two types of blastema may occur 
in WT and that each of these types exhibit different 
chemotherapeutic sensitivities, proliferative properties, 
and abilities to undergo apoptosis or necrosis [53]. To date, 
the molecular effects of therapy on WT and the factors 
that produce chemoresistance in this tumour are not well 
understood. The identification of new prognostic/response 
factors for WT would enable the stratification of patients 
for optimal clinical strategy. Therefore, biomarkers like 
MDR3 could provide oncologists with a novel tool to 
identify patients with a high risk of recurrence in order to 
apply an appropriate therapy.
For an effective treatment design for WT patients, the 
role of multidrug resistance proteins must be considered. 
The role of transporters has been described as inducers 
of chemoresistance in several studies. In paclitaxel-, 
doxorubicin- and vincristine-resistant cell lines (colon 
and ovarian cancer cell lines), an increased expression of 
several drug resistance genes was identified [35]. Also, 
in meduloblastoma cell lines, the inhibition of ABC 
transporters (MDR3 and others) increased the efficacy of 
radiation therapy [54]. Resistance to chemotherapy may be 
due to high expression of multidrug resistance mechanisms 
already present in tumor cells before treatment, and/or it is 
also possible that chemotherapy modulates the expression 
of multidrug resistance proteins reducing treatment 
efficacy. Several studies showing that expression of MRP1 
and MDR3, among others multidrug resistance genes may 
induce or increase after chemotherapy in pediatric tumors, 
soft tissue sarcomas and malignant melanoma [33, 48, 55]. 
In the SIOP-93-01 protocol, vincristine and actinomycin 
D treatment were given to the patient with localized 
tumor, and doxorubicin was included in patients with 
metastatic disease. It was known that MDR3 and MRP1 
confer resistance to a variety of drugs like vincristine, 
actinomycin D and doxorubicin [30, 56–58]. In addition 
among these drugs, only, vincristine had been described 
as a MRP1 substrate [25, 59]. Our results suggested that 
the increased of MDR3 and MRP1 expression in high 
risk and blastemal WT conferred resistance to first line 
WT chemotherapy treatment. We hypothesize that this 
tumors had more active the efflux pumps and decreased 
the intracellular accumulation of this drugs due to the high 
expression of MDR3 and MPR1.
It will be interesting to explore the inhibition of 
transporters as an adjuvant treatment to the standard 
treatment of WT patients. Several studies have 
demonstrated that inhibition of multidrug resistance 
proteins improves the results of treatment-resistant 
tumours. For example, ovarian cancer cells inhibited 
by siRNA against MDR3 showed reversed resistance 
to paclitaxel [54, 60]. In neuroblastoma cells, an MRP1 
inhibitor increased reversal of the therapeutic index of 
chemotherapy in mouse models [61]. Currently, several 
drugs associated with drug-induced liver injury (DILI), 
such as chlorpromazine, imipramine, itraconazole 
and haloperidol, are being tested as MDR3 inhibitors. 
However, these inhibitors are associated with undesirable 
side effects like liver damage [62]. The development of 
more specific peptidomimetic inhibitors, glutathione-
conjugate analogs (MRP1 inhibitor), could prevent these 
adverse outcomes [63].
In summary, our findings suggest that MDR3 and 
MRP1 could have an important role in drug resistance 
in WT treatment. In addition, we have described a 
possible new biomarker for stratification of the WT 
blastemal subtype. We demonstrated that low expression 
of MDR3 in the blastemal subtype is associated with a 
good prognosis in this high-risk tumour. In the future, it 
will be interesting to perform prospective studies with 
larger number of samples to confirm MDR3 expression 
as a clinical biomarker for WT prognosis and treatment 
outcome.  
MATERIALS AND METHODS
Patients and clinical samples
This retrospective study included two different 
sample series obtained between 1993 and 2006. Series 
1 comprised 46 frozen tumors with 40 normal kidneys (no 
tumoral kidneys). In 40 cases, normal kidney and tumor 
paired samples could be obtained. From 6 patients there 
was only tumoral tissue without normal kidney available. 
Series 2 comprised a Tissue Microarray (TMA) with 31 
paraffin-embedded samples. This series consisted of 
9 paired tumor and normal kidney, and 22 tumoral samples 
with no matched non tumoral kidney. The control group 
(normal kidney) consisted of renal tissue from the non 
tumoral part of the resected specimen following tumor 
nephrectomy. Pathologists selected the farthest region to 
the tumor. All samples were analyzed by two experienced 
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pathologists, who confirmed that the tumor samples were 
correctly identified as WT and the control kidneys did 
not present any morphological alteration. Histological 
stratification of the samples was performed according 
to SIOP [14] classification and the tissue samples were 
obtained from the Department of Pathology at the Hospital 
Universitario Virgen del Rocío (Seville, Spain). Approval 
of the Ethics Committee of this institution was obtained 
and written informed consent was obtained before 
registration of the patients from the HUVR-IBiS Biobank. 
The patient characteristics are summarized in Table 1. 
Patients treatment
All patient series were treated by neoadjuvant 
chemotherapy before nephrectomy according to the 
SIOP-93-01 protocol. Patients with localized disease were 
treated with vincristine and actinomycin D during 4 weeks 
and those with metastatic disease received vincristine, 
actinomycin D and doxorubicin during 6 weeks. SIOP 
preoperative treatment protocol is summarized in Table 2.
mRNA expression analysis
The expression of selected genes was analyzed by 
qRT-PCR. RNA was isolated from 88 frozen samples 
(40 kidneys and 46 WT) from which sufficient material 
was available with the miRVana miRNA Isolation Kit 
(Ambion; Life Technologies, NY, USA). The quantity and 
quality of the total RNA was determined with a Nanodrop 
ND-2000 Spectrophotometer (Thermo Scientific). Prior 
reverse transcription was performed using the TaqMan 
Reverse Transcription Kit (Applied Biosystems; Life 
Technologies) in the GeneAmp PCR 9700 system and 
qRT-PCR amplification with the TaqMan Universal 
PCR Master Mix (Applied Biosystems). All qRT-PCR 
measurements were obtained in a 7900HT Fast Real Time 
PCR System with the ExpressionSuite Software v1.0 
(Applied Biosystems). Table 3 summarizes the Taqman 
probes utilized in this study.
Protein analysis
 Proteins were extracted from kidney and WT 
frozen tissues in RIPA buffer (150 mM NaCl, 1% (v/v) 
NP40, 50 mM Tris-HCl pH 8.0, 0.1% (v/v) SDS, 1 mM 
EDTA and 0.5% (w/v) deoxycholate) supplemented with 
10 mM NaF and 2 mM NaOv. Samples were incubated for 
20 min on ice and centrifuged for 15 min at 13000 r.p.m. 
at 4°C. Supernatants were collected and quantified using 
the BCA Protein Assay Kit (Thermo Fisher Scientific 
Inc.). Equivalent amounts of proteins were resolved by 
SDS polyacrylamide gel electrophoresis, and transferred 
to polyvinylidene difluoride membranes (Immobilon-P, 
Millipore, Darmstadt, Germany). Immunoblotting was 
performed using the following antibodies: anti-ABCB4 
Table 1: Clinicopathological features of the tumor samples
Series 1 Series 2
Samples Frozen Paraffin 
Number of samples 46 31


















(Abcam-ab184878) overnight at 1:200 dilution; anti-
MRP1 (Abcam-ab137406) overnight at 1:200 dilution; 
anti-β-actin (A5441 clone AC-15) for 1.5 h at 1:10000 
dilution; anti-rabbit IgG, HRP (Cell Signaling, ref#7074) 
for 1 h at 1:10000; anti-mouse IgG-HRP (Cell Signaling, 
ref#7076) for 1 h at 1:10000. Protein bands were 
visualized using the Clarity Western ECL Substrate 
chemiluminescence detection kit (Bio-Rad, ref#170-
5060). All of the antibodies were previously analyzed for 
antigen specificity in our laboratory, all conditions being 
optimized for specific antigen detection, with elimination 
of nonspecific reactivity.
TMA and Immunohistochemistry (IHC)
 Tissue sections (5 µm) from formalin-fixed paraffin-
embedded (FFPE) of WT were stained with hematoxylin 
and eosin. Representative malignant areas from 31 WT 
patients were carefully selected from the stained sections 
of each tumour, and two 1 mm diameter tissue cores 
were obtained from each sample to build up the TMA in 
duplicate. Five micron-thick TMA sections were dewaxed, 
rehydrated, and immersed in 3% H2O2 aqueous solution 
for 30 minutes to exhaust endogenous peroxidase. Heat-
induced epitope retrieval was performed with 1 mM EDTA 
(pH 9.0) in a microwave oven. Sections were incubated 
overnight at 4°C with the primary antibodies anti-ABCB4 
(MDR3) (Sigma HPA053288; overnight at 1:20 dilution) 
and Anti-MRP1 (Abcam-ab137406; overnight at 1:200 
dilution). Peroxidase-labeled secondary antibodies 
and 3,3′-diaminobenzidine were applied according to 
manufacturer’s protocol (EnVision, Dako). Slides were 
then counterstained with hematoxylin and mounted. 
Sections where the primary antibody was omitted were 
used as negative controls. The plasma membrane and 
cytoplasmic was stained for both transporters (MDR3 and 
MRP1). Immunostains were scored as negative/positive 
expression according to the stain intensity and proportion 
of stained cells. Only tumoural cells evaluated as clearly 
stained were considered to be positive. The IHC results 
Table 2: SIOP 93-01 preoperative treatment protocol




Vincristine 1.5 mg/m2 Intravenous 1st and 3th
Actinomycin D 45 µg/kg intravenous 1st to 4th
Metastatic Stage
Vincristine 1.5 mg/m2 intravenous 1st -3th-5th
Actinomycin D 45 µg/kg intravenous 1st to 6th
Doxorrubicin 50 mg/m2 intravenous 1st and 5th
Table 3: TaqMan Gene Expression probes employed for qRT-PCR
Genes Brand Reference Amplicon Length
BCRP1 Applied Biosystems Hs01053790_m1 83 bp
GAPDH Applied Biosystems Hs99999905_m1 93 bp
HRPT1 Operon custom design 149bp
MDR1 Applied Biosystems Hs00184500_m1 67 bp
MDR3 Applied Biosystems Hs00240956_m1 73 bp
MRP1 Applied Biosystems Hs01561502_m1 69 bp
MRP2 Applied Biosystems Hs00166123_m1 75 bp
MRP3 Applied Biosystems Hs00978473_m1 57 bp
MVP1 Applied Biosystems Hs00245438_m1 65 bp
TEP1 Applied Biosystems Hs00200091_m1 66 bp
TPT1 Applied Biosystems Hs02621289_g1 131 bp
vPARP Applied Biosystems Hs00173105_m1 118 bp
HRPT1 Primers Sequence
Forward 5′ - CAGCCCTGCCGTCGTCGTGATA - 3′
Reverse 5′ - AGCAAGACGTTCAGTCCTGTC - 3′
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were evaluated by two pathologists (E.A. and C.S.) who 
scored the average expression of markers in duplicate 
samples. 
Statistical analysis
 Gene expression differences between control 
(kidney) and WT were evaluated with the Mann–Whitney 
U-test for two groups, and with the Kruskal–Wallis test 
for more than two groups, followed by Dunn’s multiple 
comparison post test. Paired samples t-test was applied 
to compare the mean level of expression within the 
same specimens. The Spearman´s Rank test was used to 
quantify the correlation of expression between different 
genes. Fisher´s exact test was used to evaluate differences 
between immunohistochemical expression detection 
of MDR3 and MRP1. The disease-free survival time 
was analyzed using the Kaplan–Meier estimator and 
the Wilcoxon test. For all analyses, P-values of ≤ 0.05 
were considered statistically significant. Analyses were 
performed using the Prism 4.0 software (GraphPad).
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